Cefazolin
(Redirected from Ancef)
General
- Type: 1st gen Cephalosporin
- Dosage Forms: powder for injection
- Dosage Strengths: 500mg; 1, 2, 10, 20, 100, 300g
- Routes of Administration: IV, IM
- Common Trade Names: Ancef
Adult Dosing
General
- Mild: 250-500mg IM/IV 8h
- Mod-Severe: 500-1000mg IM/IV q6-8h
- Life Threatening: 1-1.5g IM/IV q6h
- Max: 12g/day
UTI, Uncomplicated
- 1g IM/IV q12
Pneumococcal Pneumonia
- 500mg IM/IV q12
Endocarditis Prophylaxis, Dental
- 1g IM/IV x1 (30-60 min before procedure)
Pediatric Dosing
General (<7 Days)
- 40mg/kg/day IM/IV divided q12h
- First Dose: 20mg/kg IM/IV x 1
- Max 6g/day
General (>7 Days - 1 Month)
- <2000g
- 40mg/kg/day IM/IV divided q12h
- First Dose: 20mg/kg IM/IV x 1
- Max 6g/day
- >2000g
- 60mg/kg/day IM/IV divided q8h
- First Dose: 20mg/kg IM/IV x 1
- Max 6g/day
General (>1 Month)
- 25-100mg/kg/day IM/IV divided q6-8h
- First Dose: 20-33mg/kg IM/IV x 1
- Max 6g/day
Community Acquired Pneumonia (>3 Months)
- 150mg/kg/day IM/IV divided q8h x 10 days
- First Dose: 50mg/kg IM/IV x 1
- May switch to PO regimen when able
Special Populations
- Pregnancy: B
- Lactation: Safe
- Renal
- Adult
- CrCl 35-54: give q8
- CrCl 11-34: give usual dose x1, then decrease dose 50% and give q12h
- CrCl <10: give usual dose x1, then decrease dose 50% and give q18-24h
- Hemodialysis: give 0.5-1g supplement
- Peritoneal dialysis: 500mg q12h
- Pediatric
- CrCl 40-70: give usual dose x 1, then decrease daily dose 40% and give q12h
- CrCl 20-39: give usual dose x 1, then decrease daily dose 75% and give q12h
- CrCl 5-19: give usual dose x 1, the decerase daily dose 90% and give q24h
- CrCl <5: not defined
- Hemodialysis: give supplement
- Peritoneal dialysis: no supplement
- Adult
- Hepatic (Adult & Pediatric)
- Not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Neutropenia
- Thrombocytopenia
- Anaphylaxis
- Stevens-Johnson Syndrome
- Nephrotoxicity
- Seizures
- Clostridium difficile
Common
- Diarrhea
- Rash
- Nausea and Vomiting
- Abdominal Pain
- Anorexia
- Transaminitis
- Urticaria
- Thrombophlebitis
Pharmacology
- Half-life: 1.8h (3.7 ESRD)
- Metabolism: minimally metabolized in liver; CYP450
- Excretion: Urine
- Mechanism of Action: Bactericidal; inhibits cell wall mucopeptide synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014
- Epocrates